Aadi Bioscience Inc expected to post a loss of 58 cents a share - Earnings Preview

Whitehawk Therapeutics

08/05/2023 17:56

* Aadi Bioscience Inc  AADI.OQ   AADI.O  is expected to show
a
rise in quarterly revenue when it reports  results on May 10. 
    * The Pacific Palisades California-based  company is
expected to
report  a 137.6% increase in revenue to $5.481 million from
$2.31 million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Aadi Bioscience Inc
is
for a loss of 58 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 6.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $41​, above​ its last closing price of $8.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.71      -0.52     Beat    26.8
 Sep. 30 2022  -0.74       -0.74      -0.68     Beat    8.4
 Jun. 30 2022  -0.74       -0.75      -0.87     Missed  -16​
 Mar. 31 2022  -0.71       -0.71      -0.66     Beat    7.3
 ​​Dec.        -0.67       -0.98      -0.77     Beat    21.6
 31 2021                                                
 Sep. 30 2021  -0.66       -0.66      -1.36     Missed  -105​
 Jun. 30 2021  -6.00       -6.00      -1.35     Beat    77.5
 Mar. 31 2021  -1.35       -1.35      -1.35     Met     0
 This summary was machine generated May 8 at 16:56 GMT.  All
figures in US dollars  unless otherwise stated